GSK, Vernalis in cancer deal potentially worth $200M

GlaxoSmithKline agreed to pay Vernalis as much as $200 million, including $6 million upfront, in relation to the biotech firm's cancer research. GSK will oversee preclinical development of compounds from studies and also have an option to license any of those treatments.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN